Surgical site infection · women with urinary stress incontinence undergoing continence surgery
It is very uncertain whether prophylactic antibiotics (single or combined drugs) changes number of surgical site infections (SSIs) before discharge compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Number of major adverse effects defined by the study, before discharge · women with urinary stress incontinence undergoing continence surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of symptomatic UTIs or bacteriuria before discharge · women with urinary stress incontinence undergoing continence surgery
It is very uncertain whether prophylactic antibiotics (single or combined drugs) changes number of symptomatic UTIs or bacteriuria before discharge compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Febrile morbidity · women with urinary stress incontinence undergoing continence surgery
It is very uncertain whether prophylactic antibiotics (single or combined drugs) changes number of women with febrile morbidity at hospital discharge compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Number of women with sepsis or bacteraemia at hospital discharge · women with urinary stress incontinence undergoing continence surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mesh exposure · women with urinary stress incontinence undergoing continence surgery
It is very uncertain whether prophylactic antibiotics (single or combined drugs) changes number of mesh exposures within six weeks after the operation compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Proportion of susceptible participants who did not experience any motion sickness symptoms under natural conditions Assessed by: self‐reported questionnaires6,7 · patients with motion sickness
Antihistamines probably leads to higher proportion of susceptible participants who did not experience any… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of susceptible participants who did not experience any motion sickness symptoms under experimental conditions Assessed by: calculated based on head movements tolerated (rotating chair); MSAQ · patients with motion sickness
1 finding from 1 review
Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms · patients with motion sickness
The review found no eligible studies for this question.
1 finding from 1 review
Physiological measures: heart rate and core temperature · patients with motion sickness
The review found no eligible studies for this question.
1 finding from 1 review
Physiological measures: gastric tachyarrhythmia10 Assessed by: electrogastrography · patients with motion sickness
1 finding from 1 review
Adverse effects: 1. Sedation · patients with motion sickness
Antihistamines may leads to higher adverse effects: sedation Assessed by: adverse effect questionnaire… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: impaired cognition Assessed by: adverse effect questionnaire (presence or absence given numerical values) · patients with motion sickness
Antihistamines showed no clear difference in adverse effects: impaired cognition Assessed by: adverse effect… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects ‐ Blurred vision No of patients with blurred vision · patients with motion sickness
Antihistamines showed no clear difference in adverse effects: blurred vision Assessed by: adverse effect… compared with placebo (low certainty).
1 finding from 1 review
Days missed from work or school · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
ADHD symptoms · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
3 findings from 1 review
no estimate extracted
16 studies · 3799 participants
Very low
no estimate extracted
18 studies · 4183 participants
Very low
no estimate extracted
3 studies · 1005 participants
Very low
Serious adverse events Median · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Quality of life, self‐rated at post‐treatment · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Proportion of participants experiencing adverse events · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review